ISIN | LU1334634703 |
---|---|
Valorennummer | 30674042 |
Bloomberg Global ID | |
Fondsname | Crossfund Sicav - Crossinvest Healthcare Fund B EUR |
Fondsanbieter |
Crossinvest SA
Lugano, Schweiz Telefon: +41 91 911 88 88 E-Mail: info@crossinvest.ch Web: www.crossinvest.ch |
Fondsanbieter | Crossinvest SA |
Vertreter in der Schweiz |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(en) |
FundPartner Solutions (Suisse) SA Genève 3 |
Anlagekategorie | Aktienfonds |
EFC-Kategorie | |
Anteilskategorie | Accumulation |
Domizilland | Luxemburg |
Konditionen bei der Ausgabe | Kombination von Ausgabekommission zugunsten der Fondsleitung und Transaktionsgebühr zugunsten des Fonds |
Konditionen bei der Rücknahme | Kombination von Rücknahmekommission zugunsten der Fondsleitung und Transaktionsgebühr zugunsten des Fonds |
Investment-Strategie *** | The investment objective of the Sub‐Fund is to achieve a long term capital appreciation by pursuing sector focus exposure opportunities in companies involved in health and personal care. These companies could participate in the research, clinical development or commercialization of medicines, equipment or services for disease treatment or life style improvement. The investment focus will be on industry leaders that offer premium growth and/or profitability prospects, pipeline and valuation upside. The Sub‐Fund is actively managed. The Sub‐Fund has no benchmark index and is not managed in reference to a benchmark index. |
Besonderheiten |
Aktueller Preis * | 129.39 EUR | 21.11.2024 |
---|---|---|
Vorheriger Preis * | 129.11 EUR | 20.11.2024 |
52 Wochen Hoch * | 148.47 EUR | 30.08.2024 |
52 Wochen Tief * | 121.47 EUR | 28.11.2023 |
NAV * | 129.39 EUR | 21.11.2024 |
Ausgabepreis * | 129.39 EUR | 21.11.2024 |
Rücknahmepreis * | ||
Schlusskurs * | ||
Indikativer Minimalpreis | ||
Fondsvermögen *** | 63'097'000 | |
Anteilsklassevermögen *** | 502'755 | |
Trading Information SIX |
YTD-Performance | -0.42% |
29.12.2023 - 21.11.2024
29.12.2023 21.11.2024 |
---|---|---|
YTD-Performance (in CHF) | -0.38% |
29.12.2023 - 21.11.2024
29.12.2023 21.11.2024 |
1 Monat | -7.88% |
21.10.2024 - 21.11.2024
21.10.2024 21.11.2024 |
3 Monate | -11.60% |
21.08.2024 - 21.11.2024
21.08.2024 21.11.2024 |
6 Monate | -6.25% |
21.05.2024 - 21.11.2024
21.05.2024 21.11.2024 |
1 Jahr | +6.03% |
21.11.2023 - 21.11.2024
21.11.2023 21.11.2024 |
2 Jahre | -0.55% |
21.11.2022 - 21.11.2024
21.11.2022 21.11.2024 |
3 Jahre | -11.83% |
22.11.2021 - 21.11.2024
22.11.2021 21.11.2024 |
5 Jahre | +9.13% |
21.11.2019 - 21.11.2024
21.11.2019 21.11.2024 |
Kapitalbeteiligungsquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anteil am Gesamtvermögen in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immobilienquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Novo Nordisk AS Class B | 6.25% | |
---|---|---|
AbbVie Inc | 4.73% | |
UnitedHealth Group Inc | 4.63% | |
AstraZeneca PLC | 4.06% | |
Merck & Co Inc | 4.01% | |
Eli Lilly and Co | 3.80% | |
Thermo Fisher Scientific Inc | 3.77% | |
Johnson & Johnson | 3.54% | |
Roche Holding AG | 3.22% | |
Stryker Corp | 3.09% | |
Letzte Daten-Aktualisierung | 31.07.2024 |
TER | |
---|---|
Datum TER | |
Performance Fee *** | 15.00% |
PTR | |
Max. Management Fee *** | 1.80% |
Ongoing Charges *** | 2.45% |
SRRI ***
|
|
Datum SRRI *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |